US Stock MarketDetailed Quotes

ORGO Organogenesis

Watchlist

2.460
-0.035-1.40%

Trading Jun 17 12:36 ET

326.13MMarket Cap61.50P/E (TTM)

Organogenesis Stock Forum

TrendTrader

May 10 13:52

Over 3.2 can see 3.5 and 3.75-3.8

$Organogenesis(ORGO.US)$

Trytosaveabit

May 9 15:52

$Organogenesis(ORGO.US)$ revenue of $110.0 million for the first quarter of 2024, an increase
of $2.3 million compared to net revenue of $107.6 million for the first
quarter of 2023. Net revenue for the first quarter of 2024 consists of:
-- Net revenue from Advanced Wound Care products of $103.9 million,
an increase of 3% from the first quarter of 2023.
-- Net revenue from Surgical & Sports Medicine products of $6.1
million, a decrease of 9% from the first quarter of 2023.
-- Net loss of ...

Stock Region

May 2 13:26

Therapeutics Company Achieves Promising Clinical Trial Results For Knee Osteoarthritis Therapy

The implications of ReNu’s success extend far beyond symptom management.
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...

Jaguar8

May 2 06:04

$Organogenesis(ORGO.US)$
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...

beachlover

Apr 4 10:22

$Organogenesis(ORGO.US)$ 🔥HUBC🔥

Moomoo AI

Mar 4 08:06

Despite poor earnings, the high P/E ratio indicates investors anticipate strong future growth, justifying a higher stock price. Unless earnings significantly deteriorate, the share price should remain strong.

Organogenesis Holdings Inc.'s (NASDAQ:ORGO) P/E Is On The Mark

Moomoo AI

Jan 14 06:42

Albert Erani's recent sale of Organogenesis Holdings shares, the largest insider sale in the past year, raises concerns despite the high sale price. The absence of insider buying and presence of selling suggest a cautious outlook, despite high insider ownership.